ArticleCase reports in oncology
A Long-Term Survival Case Report of a Patient with Pulmonary Sarcomatoid Carcinoma Accompanied by Brain Metastasis: Implications for Immunotherapy.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare and highly malignant pathological subtype of non-small cell lung cancer. Most patients are diagnosed at an advanced stage. Chemotherapy is a treatment option to be considered. However, PSC is not sensitive to chemotherapy. The high expression of PD-L1 in PSC and the abundant infiltration of immune cells suggest that immunotherapy may be effective for PSC. Case Presentation: Here, we present a case of PSC. The patient was diagnosed with advanced lung cancer with metastases to the brain, liver, left adrenal gland, and bone. After 4 cycles of chemotherapy combined with camrelizumab, the patient received monotherapy with immunotherapy. After the progression of brain metastases, brain radiotherapy was added. It has been 43 months since the patient was diagnosed with lung cancer. The patient's condition remains stable and there are no obvious side effects. Conclusion: For patients with PSC, genetic testing is necessary. The efficacy of immunotherapy in patients with PSC is worthy of expectation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.